The subcutaneous formulation of daratumumab makes treatment a faster and more tolerable process for patients with multiple ...

Using the latest data and perspectives, an international expert panel releases updated recommendations for optimal insulin ...

The 12–month study involved 233 subjects, including 217 patients under the age of 18. Only 14% of the patients who received subcutaneous injections of immunoglobulin missed work or study due to ...

In December 2024, the Food and Drug Administration (FDA) approved the PD-1 inhibitor nivolumab (Opvido Qvantig) for use as a subcutaneous injection. Read on to learn more about this new approach ...

Stem cell injections are one such treatment. A new review my colleagues and I published this week finds that evidence of their benefits and harms remains elusive. Stem cells are already ...

[Operator Instructions]. As a reminder ... of biologics with proven bioavailability comparable to a subcutaneous injection. Our RaniPill technology is currently being evaluated across several ...

Subcutaneous immunotherapy injections work the same way as their intravenous counterparts — by changing or enhancing a person’s immune responses to cancer. Immunotherapy for cancer is a broad ...

Tens of billions of dollars in sales are at stake. Merck & Co.’s Keytruda and Bristol Myers Squibb’s Opdivo are both due to lose U.S. patent protection in 2028, and a switch to subcutaneous injection ...